Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02867644 | Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer(HYCOREMA) | N/A | terminated | Aug 16, 2016 | Institut de Cancérologie de Lorraine | Results not achievable after interim analysis conclusions and recruting difficulty | Efficacy / futility |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | — | withdrawn | Mar 2, 2020 | University of Arizona | Principal investigator is moving to a new institution. Study is closing. | Investigator |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive… | Phase 2 | withdrawn | Feb 10, 2022 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT02229149 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for… | Phase 2 | terminated | Aug 29, 2014 | US Oncology Research | per Sponsor request | Other (stated, no rule matched) |
| NCT03386162 | SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant…(SAFIR-PI3K) | Phase 2 | terminated | Dec 29, 2017 | UNICANCER | Study was halted Prematurely for low recruitment. | Enrollment / accrual |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | — | withdrawn | Feb 13, 2020 | George Washington University | Study never initiated due to COVID pandemic, staffing changes | COVID-19 / pandemic |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA…(BRAVO) | Phase 3 | terminated | Jul 23, 2013 | Tesaro, Inc. | The study was terminated due to futility. | Efficacy / futility |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and… | Phase 2 | terminated | Apr 28, 2014 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1 | terminated | Jun 17, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT01649505 | Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast… | N/A | terminated | Jul 25, 2012 | OHSU Knight Cancer Institute | Low patient enrollment and no clinical findings. | Enrollment / accrual |
| NCT01257932 | Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse… | — | withdrawn | Dec 10, 2010 | University of California, Irvine | According to the NIH definition of clinical trial studies, this study does not meet requirement to… | Other (stated, no rule matched) |
| NCT01277263 | Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse… | — | withdrawn | Jan 14, 2011 | University of California, Irvine | Not a Clinical Trial study | Other (stated, no rule matched) |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast… | Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | Due to the fact that the sponsor decided not to move forward with the development of M7824 | Sponsor / business decision |
| NCT04142060 | Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone…(ARIANNA) | Phase 2 | terminated | Oct 29, 2019 | SOLTI Breast Cancer Research Group | Lack of effectiveness | Other (stated, no rule matched) |
| NCT04460430 | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative…(NEREA) | Phase 2 | terminated | Jul 7, 2020 | SOLTI Breast Cancer Research Group | premature termination due to lack of funding | Funding |
| NCT05523063 | Effect of Physical Activity in Patients With Breast Cancer.(APACAM) | — | withdrawn | Aug 31, 2022 | Hospices Civils de Lyon | Study classified as out of scope by the Ethics Committee (not a project involving human person). | Other (stated, no rule matched) |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | — | terminated | Feb 23, 2016 | University of Maryland, Baltimore | Unable to meet accrual goal | Enrollment / accrual |
| NCT04535895 | Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy | N/A | withdrawn | Sep 2, 2020 | Medical University of Graz | Treatment standard has changed | Other (stated, no rule matched) |
| NCT02913729 | Pre- Versus Postoperative Accelerated Partial Breast Irradiation(PAPBI-2) | N/A | terminated | Sep 26, 2016 | The Netherlands Cancer Institute | Lack of accrual | Enrollment / accrual |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor… | Phase 1 | terminated | Apr 25, 2017 | Jonsson Comprehensive Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT02113553 | Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | Phase 2 | terminated | Apr 14, 2014 | Armando Santoro, MD | target population not reached | Other (stated, no rule matched) |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation… | Phase 2 | terminated | Jul 30, 2014 | National Cancer Institute (NCI) | Eli Lilly prematurely terminated the study. | Other (stated, no rule matched) |
| NCT04876378 | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone… | — | terminated | May 6, 2021 | University of California, San Francisco | Funding | Funding |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | N/A | terminated | Nov 21, 2018 | NYU Langone Health | technical difficulties for scans on the research MRI system | Other (stated, no rule matched) |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive… | Phase 1 / Phase 2 | terminated | May 29, 2015 | Vanderbilt-Ingram Cancer Center | Interim analysis - toxicity | Safety / toxicity |
| NCT02514837 | Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer(RTM) | — | withdrawn | Aug 4, 2015 | University of Edinburgh | No funding | Funding |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04102618 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer(AWARE-1) | Early Phase 1 | terminated | Sep 25, 2019 | Oncolytics Biotech | Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the… | Enrollment / accrual |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | N/A | withdrawn | Apr 16, 2020 | Xoft, Inc. | Lack of site participation | Other (stated, no rule matched) |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the… | Phase 2 / Phase 3 | terminated | Sep 17, 2018 | ERYtech Pharma | sponsor decision | Sponsor / business decision |
| NCT03791736 | Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele…(SANDOSTATINE) | N/A | terminated | Jan 3, 2019 | Institut Cancerologie de l'Ouest | The surgical technique is no longer used | Other (stated, no rule matched) |
| NCT04685551 | Improving Survivorship Among Minority Cancer Dyads | N/A | withdrawn | Dec 28, 2020 | Charles Drew University of Medicine and Science | Study not funded | Funding |
| NCT03147040 | AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer(GELATO) | Phase 2 | terminated | May 10, 2017 | The Netherlands Cancer Institute | At interim analysis insufficient benefit was observed to continu the study | Efficacy / futility |
| NCT02569489 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women… | Phase 1 | withdrawn | Oct 6, 2015 | HUYABIO International, LLC. | Reconsideration of Study Design; plan for alternative protocol | Other (stated, no rule matched) |
| NCT02826512 | A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer… | Phase 2 | terminated | Jul 11, 2016 | The Netherlands Cancer Institute | Not enough eligble patient can be found, too many screen failures | Other (stated, no rule matched) |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With…(SANDPIPER) | Phase 3 | terminated | Jan 16, 2015 | Hoffmann-La Roche | The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical… | Drug supply |
| NCT04116281 | Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery | N/A | suspended | Oct 4, 2019 | Universidade Federal de Sao Carlos | Pandemic situation | COVID-19 / pandemic |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | Phase 2 | withdrawn | Feb 7, 2022 | MedSIR | Funder decided to not continue the study | Other (stated, no rule matched) |
| NCT05063604 | Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer…(CAMAD) | Phase 2 | terminated | Oct 1, 2021 | Hospital Universitari de Bellvitge | The CAMAD clinical trial has been terminated due to difficulties in recruiting patients. | Enrollment / accrual |
| NCT02562612 | Study of SM-88 in Advanced Cancers | Phase 1 / Phase 2 | withdrawn | Sep 29, 2015 | Tyme, Inc | Study was never initiated. Never established sites or enrolled subjects. | Enrollment / accrual |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With…(TOPAZ) | Phase 1 / Phase 2 | withdrawn | Aug 13, 2020 | Reva Basho | Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer. | Other (stated, no rule matched) |
| NCT02035085 | 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction(CS-1000) | Phase 1 | withdrawn | Jan 14, 2014 | Johns Hopkins University | Drugs/devices discontinued | Other (stated, no rule matched) |
| NCT04630210 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients…(AteBrO) | Early Phase 1 | withdrawn | Nov 16, 2020 | Universitaire Ziekenhuizen KU Leuven | Insufficient resources | Other (stated, no rule matched) |
| NCT04397029 | Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening… | N/A | terminated | May 21, 2020 | George Washington University | The benefit of completing the study was not worth exposing subjects to the risk during COVID.… | COVID-19 / pandemic |
| NCT04560439 | Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast… | N/A | withdrawn | Sep 23, 2020 | City of Hope Medical Center | Funding | Funding |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With… | N/A | withdrawn | Feb 17, 2022 | City of Hope Medical Center | PI withdrawn | Other (stated, no rule matched) |
| NCT00754312 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of… | Phase 1 | terminated | Sep 17, 2008 | Syndax Pharmaceuticals | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 20, 2022source: clinicaltrials